Nasus Pharma shifts shareholder meeting to virtual only

Nasus Pharma Ltd. is changing its upcoming Special General Meeting of Shareholders to a fully virtual format because of the security situation in Israel and limits on public gatherings.

Accepted by SEC EDGAR 03/04/2026 - 08:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Nasus Pharma Ltd. is changing its upcoming Special General Meeting of Shareholders to a fully virtual format because of the security situation in Israel and limits on public gatherings. Shareholders will not be able to attend in person and must join online instead.

The meeting remains scheduled for March 5, 2026 at 2:00 p.m. Israel time. Investors can access the meeting via Zoom using the published meeting link, ID, and passcode, allowing participation and voting remotely while maintaining the original timing of the meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nasus Pharma Ltd. (NSRX) announce in its March 2026 Form 6-K?

Nasus Pharma announced that its Special General Meeting of Shareholders will be held only in a virtual format. The shift responds to Israel’s security situation and public gathering restrictions, ensuring the meeting proceeds as scheduled while allowing shareholders to participate remotely.

Why is Nasus Pharma (NSRX) moving its Special General Meeting to a virtual format?

The company is moving the Special General Meeting online due to the security situation in Israel and related restrictions on public gatherings. This approach lets the meeting proceed safely while maintaining shareholder access and preserving the original agenda and timing previously communicated.

When will Nasus Pharma’s (NSRX) Special General Meeting of Shareholders take place?

The Special General Meeting is scheduled for Thursday, March 5, 2026 at 2:00 p.m. Israel time. Only virtual attendance is allowed, replacing the prior physical location while keeping the previously announced date and time unchanged for shareholders.

Can Nasus Pharma (NSRX) shareholders attend the March 2026 meeting in person?

Shareholders cannot attend in person; the meeting is entirely virtual. Participation will be through an online Zoom meeting using the provided link, meeting ID, and passcode, ensuring remote access in light of Israel’s security and gathering restrictions.

How can Nasus Pharma (NSRX) shareholders virtually access the Special General Meeting?

Shareholders can join via a Zoom link that includes a specific meeting ID and passcode. These details are given in the announcement so investors can log in at the scheduled time, enabling remote attendance and participation despite the absence of a physical venue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On March 4, 2026, Nasus Pharma Ltd. (the “Company”) announced that, due to the security situation in the State of Israel and restrictions on public gatherings, the location of the Company’s Special General Meeting of Shareholders (the “Meeting”) has been changed to a virtual meeting format only.

Shareholders will not be able to attend the Meeting in person. As previously announced by the Company in its Report of Foreign Private Issuer on Form 6-K on January 29, 2026, the Meeting will be held on Thursday, March 5, 2026 at 2:00 p.m. Israel time. Shareholders may attend the Meeting virtually at:

	●	Link: https://zoom.us/j/94874269962?pwd=OWuiu8uqYLCInuxNe5vRg2w2BiqziZ.1
	●	Meeting ID: 948 7426 9962
	●	Passcode: 229406

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: March 4, 2026	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer